DLX6 and neoplasm: However, because of the limited number of enrolled patients and high false positive and negative results due to the use of serum exosome lncRNA DLX6-AS1 alone as the prognosis factor of patients with CC, they suggested that a combination with other known tumor biomarkers and clinicopathological parameters was needed to accurately predict the clinical outcome of CC.